Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertraline.

CONTEXT: The duration of treatment after achieving a satisfactory response is unknown in the treatment of premenstrual syndrome. This information is needed in view of the improvement provided by medication vs the adverse effects and costs of drugs. OBJECTIVE: To compare rates of relapse and time to relapse between short- and long-term treatment with sertraline hydrochloride administered in the luteal phase of the menstrual cycle. DESIGN: Eighteen-month survival study with a randomized double-blind switch to placebo after 4 or 12 months of sertraline treatment. SETTING: Academic medical center. PARTICIPANTS: One hundred seventy-four patients with premenstrual syndrome or premenstrual dysphoric disorder. MAIN OUTCOME MEASURE: Relapse, defined as symptoms returning to the entry criterion level as assessed with daily ratings. RESULTS: The relapse rate was 41% during long-term treatment compared with 60% after short-term sertraline therapy, with a median time to relapse of 8 months vs 4 months (hazard ratio, 0.58; 95% confidence interval, 0.34-0.98; P = .04). Patients with severe symptoms at baseline were more likely to experience relapse compared with patients in the lower symptom severity group (hazard ratio, 2.02; 95% confidence interval, 1.18-3.41; P = .01) and were more likely to experience relapse with short-term treatment (P = .03). Duration of treatment did not affect relapse in patients in the lower symptom severity group (P = .50). Patients who demonstrated remission were least likely to experience relapse (hazard ratio, 0.22; 95% confidence interval, 0.10-0.45; P < .001). Further analysis comparing relapse in the first 6 months of placebo treatment in each group yielded similar results. CONCLUSIONS: The relapse rate was significantly greater after short-term treatment compared with long-term treatment. The relapse rate was also high during extended drug treatment. Subjects with severe symptoms at baseline were most likely to experience relapse, and relapse occurred more swiftly regardless of treatment duration. These findings suggest that the severity of symptoms at baseline and symptom remission with treatment should be considered in determining the duration of treatment. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00318773.

Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder.

This review examines the effects of antidepressant medications on premenstrual dysphoric disorder (PMDD) and the diminished quality of life (QOL) that accompanies the disorder. PMDD is a chronic condition in women that emerges in the second half of the menstrual cycle and remits during the menstrual period. The affective and behavioural symptoms of PMDD adversely affect functioning and QOL to a disabling degree, particularly in the domains of family and personal relationships, work productivity and social activities. The serotonergic antidepressants, specifically the selective serotonin reuptake inhibitors (SSRIs), are effective for PMDD. Continuous and luteal-phase dosing regimens with SSRIs are similarly effective and well tolerated. Treatment of PMDD with a serotonergic antidepressant significantly improves functioning and QOL in all studies that have systematically examined QOL issues in this disorder. Although the data show that PMDD is effectively treated with serotonergic antidepressants and that functional impairment that accompanies the disorder is also improved with treatment, the social and economic burden of PMDD continues to be widely unrecognised. Greater awareness of the effectiveness of treatments and reliable measures of the direct and indirect healthcare costs of the disorder when it remains untreated are needed.

Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis.

Because of the prevalence, chronicity and distress caused by premenstrual symptoms (PMS), diagnosis and effective treatments are important information for clinicians. The DSM-IV requires at least five specified symptoms for premenstrual dysphoric disorder (PMDD), a severe dysphoric form of PMS, while the ICD-10 requires only one distressing symptom for a diagnosis of PMS. Many women who seek treatment fall between these two diagnostic approaches, and standard diagnostic criteria for clinically significant PMS are needed. A diagnosis of PMS consists of determining the timing of the symptoms in relation to menses, meaningful change between post- and premenstrual symptom severity and a clinically significant severity of the symptoms. A differential diagnosis to distinguish PMS from other medical and psychiatric conditions is important for appropriate treatment. No hormone or laboratory test indicates a PMS diagnosis. The current diagnostic standard requires confirmation of subjective symptom reports by prospective daily diaries. Diagnostic criteria for PMS must recognize the broad range of symptoms, the temporal pattern of the symptoms and the critical issue of symptom severity, which differentiates clinically significant PMS from normal menstrual cycle changes.

Psychometric properties of a menopausal symptom list.

OBJECTIVE: To determine psychometric properties of a brief menopause symptom list and its sensitivity to menopausal status in a population-based cohort of late reproductive-age women. DESIGN: A 12-item menopause symptom list (MSL) administered in a cohort of African American and Caucasian women aged 38 to 52 years (N = 350) was psychometrically evaluated. Menopausal status of the cohort was determined by menstrual cycle dates obtained in interviews and participants' daily symptom records. Results of factor analysis were applied to longitudinal assessments of the cohort over a 3-year period. Convergent validity with other standard measures of mood, stress, health, and quality of life was determined. RESULTS: Internal consistency was found for the MSL items. Item total correlations are reported. Factor analysis identified three dimensions (psychological, somatic, and vasomotor). Multivariate analysis of cohort data over a 3-year interval showed that the menopausal symptoms increased over time (P = 0.0004) and that the identified factors were differentially associated with menopausal status. Psychological symptoms increased in the premenopausal and early transition groups but decreased in the late menopausal-postmenopausal groups (P = 0.0046 for the interaction). Vasomotor symptoms increased in both the early transition and late menopausal-postmenopausal groups (P = 0.0309 and P = 0.0543, respectively). Psychological symptoms (factor 1) had high correlations with other standard symptom measures (Center for Epidemiologic Studies-Depression Scale, r = 0.59; Zung Anxiety Scale, r = 0.65), whereas factors 2 and 3 did not, suggesting that the somatic and vasomotor symptoms were not associated with mood or health problems. CONCLUSIONS: The MSL provides a brief questionnaire with acceptable psychometric properties for assessing three dimensions of menopause-related symptoms and demonstrated sensitivity to menopausal status in a population-based cohort.